Drugs / MM-specific universal CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06006741 | Oct 2023 → Sep 2026 overdue | plasma cell myeloma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MM-specific universal CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06006741 ↗ |
| Modality | Cell therapy | “universal type of CAR-T cells” NCT06006741 ↗ |